COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
NewYork–Presbyterian Hospital · Columbia University Irving Medical Center · +61 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
2,934
total citations
- FWCI
- 360.17
- Percentile
- 100%
- References
- 161
Citations per year
Authors
46- BBBehnood BikdeliCorresponding
NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, New York Hospital Queens, Cardiovascular Research Foundation, Columbia University
- MVMahesh V. MadhavanCorresponding
NewYork–Presbyterian Hospital, Columbia University Irving Medical Center, New York Hospital Queens, Cardiovascular Research Foundation, Columbia University
- DJDavid Jiménez
Universidad de Alcalá, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
- TCTaylor Chuich
NewYork–Presbyterian Hospital, New York Hospital Queens, Columbia University
- IDIsaac Dreyfus
NewYork–Presbyterian Hospital, New York Hospital Queens, Columbia University
Topics & keywords
Topics
Keywords
- Medicine
- Antithrombotic
- Intensive care medicine
- Disease
- Thrombosis
- Pandemic
- Venous thrombosis
- Coronavirus disease 2019 (COVID-19)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BSBristol-Myers Squibb
- PPfizer
- AAstraZeneca
- SSanofi
- BHBayer HealthCare
- ESEuropean Society of Cardiology
- DDaiichi-Sankyo
- LPLEO Pharma
- NINational Institutes of HealthAwards: HL007854, T32 HL007854
- IMIrving Medical Center, Columbia UniversityAward: T32 HL007854
- NHNational Heart, Lung, and Blood InstituteAwards: HL007854, T32 HL007854